



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
Phone: 022-24822222/24930918 Fax : 022 – 2493 0534/ 2493 9633
CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/09/2014

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half Year		Year ended
		30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	27,486.10	25,671.21	24,743.97	53,157.31	47,660.63	93,443.47
	b. Other Operating Income	539.67	589.07	574.68	1,128.74	1,180.81	2,209.92
	Total Income from Operations (Net) (a+b)	28,025.77	26,260.28	25,318.65	54,286.05	48,841.44	95,653.39
2	Expenses						
	a. Cost of materials consumed	8,703.83	8,338.64	7,834.52	17,042.47	15,659.87	31,078.57
	b. Purchases of stock-in-trade	3,070.88	2,402.03	1,584.92	5,472.91	3,824.06	7,677.06
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(507.40)	437.46	43.82	(69.94)	(163.66)	(1,074.92)
	d. Employees benefits expense	3,553.23	3,718.27	3,306.69	7,271.50	6,696.70	13,184.59
	e. Depreciation and amortization expense	1,001.00	990.00	750.00	1,991.00	1,500.00	2,716.51
	f. Exchange Fluctuation Transactional (Gain)/Loss	25.97	(49.45)	131.58	(23.48)	135.16	479.29
	g. Other Expenses	7,422.79	6,578.02	7,514.08	14,000.81	13,747.45	29,299.51
	Total Expenses	23,270.30	22,414.97	21,165.61	45,685.27	41,399.58	83,360.61
3	Profit from Operations before Other Income, Finance Cost and exceptional item (1-2)	4,755.47	3,845.31	4,153.04	8,600.78	7,441.86	12,292.78
4	Other Income	520.52	173.96	680.86	694.48	832.38	3,753.77
5	Profit from Ordinary Activities before Finance Cost and exceptional item (3+4)	5,275.99	4,019.27	4,833.90	9,295.26	8,274.24	16,046.55
6	Finance Cost	225.40	132.57	189.87	357.97	336.75	612.70
7	Profit from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	5,050.59	3,886.70	4,644.02	8,937.29	7,937.49	15,433.85
8	Exchange Fluctuation Translation Gain / (Loss)	(782.29)	368.77	(617.48)	(413.52)	(1,161.64)	414.93
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+-8)	4,268.30	4,255.47	4,026.54	8,523.77	6,775.85	15,848.78
10	Exceptional Item: Revision of purchase price in respect of Sale of Russia-CIS OTC Business Undertaking	-	-	-	-	-	(6,450.00)
11	Profit before Tax (9-10)	4,268.30	4,255.47	4,026.54	8,523.77	6,775.85	9,398.78
12	Tax expenses	1,079.57	1,076.37	712.27	2,155.94	1,429.03	2,556.23
13	Net Profit for the period from Ordinary Activities after Tax (11-12)	3,188.72	3,179.10	3,314.27	6,367.83	5,346.82	6,842.55
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.16	1,695.40	1,694.24	1,696.16	1,694.24	1,694.63
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	103,086.53
16	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	3.76	3.75	3.91	7.51	6.31	8.08
	(2) Diluted	3.76	3.75	3.91	7.51	6.31	8.07

Sl. No.	PART II - Particulars	Quarter ended			Half Year		Year ended
		30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	37,501,697	37,453,963	37,385,603	37,501,697	37,385,603	37,405,427
	- Percentage of shareholding	44.22	44.18	44.13	44.22	44.13	44.15
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	47,306,528	47,315,787	47,326,197	47,306,528	47,326,197	47,326,198
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.78	55.82	55.87	55.78	55.87	55.85

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/09/2014
Pending at the beginning of the quarter	0
Received during the quarter	4
Disposed of during the quarter	4
Remaining unresolved at the end of the quarter	0

NOTES

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on November 10, 2014.
2. The statutory auditors have carried out limited review of the above financial results for the quarter ended on September 30, 2014.
3. The net sales for the quarter/half year are strictly not comparable due to the company's wholly owned subsidiary in Dubai commencing sales and distribution of the products in the Russia-CIS Countries during last quarter. This subsidiary will also undertake some of the expenses. Hence this arrangement is not expected to have significant impact on the company.
4. The company has provided depreciation based on the useful life as per Schedule II to the Companies Act, 2013.
5. The company is engaged in a single segment of activity viz. Pharmaceuticals.
6. The previous quarter's/ period's figures have been regrouped/re-stated, wherever necessary.
7. The statement of assets and liabilities as of September 30, 2014 is as under:

Particulars		AS AT 30.09.2014	AS AT 31.03.2014
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a. Share Capital	1,696.16	1,694.63
	b. Reserves and surplus	109,139.76	103,086.53
	Sub Total of Shareholders' funds	110,835.92	104,781.16
2	Non-current liabilities		
	a. Long-term borrowings	42.51	48.84
	b. Deferred tax liabilities (Net)	1,818.39	1,988.93
	c. Long-term provisions	1,358.70	1,218.70
	Sub-Total - Non-current liabilities	3,219.60	3,256.47
3	Current liabilities		
	a. Short-term borrowings	8,211.78	8,127.85
	b. Trade payables	6,036.47	5,169.08
	c. Other current liabilities	9,551.04	9,399.59
	d. Short-term provisions	513.77	3,459.06
	Sub-Total - Current liabilities	24,313.06	26,155.58
	TOTAL-EQUITY AND LIABILITIES	138,368.58	134,193.21
B	ASSETS		
1	Non-current assets		
	a. Fixed assets	32,978.37	32,852.81
	b. Non-current investments	3,951.66	3,885.67
	c. Long-term loans and advances	2,022.51	1,061.99
	Sub-Total - Non-current assets	38,952.54	37,800.47
2	Current assets		
	a. Current investments	51,412.78	49,725.74
	b. Inventories	11,697.17	11,122.70
	c. Trade receivables	26,565.48	24,805.15
	d. Cash and cash equivalents	1,259.31	1,080.30
	e. Short-term loans and advances	8,481.30	9,658.85
	f. Other current assets		
	Sub-Total - Current assets	99,416.04	96,392.74
	Total-Assets	138,368.58	134,193.21

For J.B. Chemicals & Pharmaceuticals Ltd.



Place : Mumbai
Date : November 10, 2014

J.B.Mody
Chairman & Managing Director